Cubist Systematic Strategies’s Eledon Pharmaceuticals ELDN Stock Holding History

Cubist Systematic Strategies’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-24,568	Closed	-$101K	–	3018
2024 Q4	$101K	Buy	+24,568	New	+$96.9K	﹤0.01%	2710
2022 Q4	–	Sell	-35	Closed	–	–	4328
2022 Q3	$0	Buy	35 +16	+84%	+$51	﹤0.01%	4496
2022 Q2	$0	Buy	+19	New	+$58	﹤0.01%	4404
2021 Q3	–	Sell	-600	Closed	-$5K	–	3000
2021 Q2	$5K	Sell	600 -400	-40%	-$3.77K	﹤0.01%	2874
2021 Q1	$11K	Buy	+1,000	New	+$15.1K	﹤0.01%	2781
2014 Q4	–	Sell	-103	Closed	-$252K	–	1924
2014 Q3	$252K	Buy	+103	New	+$293K	0.02%	1214

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Cubist Systematic Strategies's ELDN Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Eledon Pharmaceuticals (ELDN) in Q1 2025, closing a stake of 24,568 shares — an estimated $101K sold.

Cubist Systematic Strategies first reported a position in ELDN in Q3 2014 and held it in 6 quarters. The position peaked at $252K in Q3 2014. 83 funds tracked by Wall St. Rank hold ELDN as of Q1 2025.

Cubist Systematic Strategies reported no remaining Eledon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Cubist Systematic Strategies sold 24,568 Eledon Pharmaceuticals shares in Q1 2025, an estimated $101K.
Cubist Systematic Strategies first reported a position in Eledon Pharmaceuticals in Q3 2014 and held it in 6 quarters.
Cubist Systematic Strategies's Eledon Pharmaceuticals position peaked at $252K in Q3 2014.
83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.